3 ms·
Those drugs are going up in price so they reflect the prices of new orphan drug launches. And they can do it since competition won’t bother to jump through FDA
by refurb 7y ago
Those drugs are going up in price so they reflect the prices of new orphan drug launches.
And they can do it since competition won’t bother to jump through FDA hoops.
- HarryHirsch 7y agojump through FDA hoops Not that again. Bioequivalence is important so that a patient can take Levothyroxin 75 μg from Ranbaxy one month and Levothyroxin 75 μg from Teva next month and notice no difference. Unfortunately, the market for orphan drugs is so small that it's impossible to recover the outlays.
- refurb 7y agoJust as an aside, once you start on a thyroid medication, it’s recommended you stick with that manufacturer. Yes, they are bioequivalent, but to the FDA that means 80%-125% of the originator. But yes, these markets where formally cheap drugs get 100x price increases are tiny markets where the outlay to get FDA approval is more than they’d make on it.